ARTICLE | Clinical News
Fevipiprant: Phase II data
August 15, 2016 7:00 AM UTC
Top-line data from a double-blind, U.K. Phase II trial in 61 patients with persistent, moderate to severe asthma and an elevated sputum eosinophil count showed that twice-daily 225 mg oral fevipiprant...